ROTATION DESCRIPTION

ROTATION TITLE
Pharmacotherapy Clinic (PGY2)

PURPOSE
The Postgraduate Year Two (PGY2) Ambulatory Care Residency Program is designed to develop accountability; practice patterns; habits; and expert knowledge, skills, attitudes, and abilities in the respective advanced area of pharmacy practice. The Ambulatory Care Residency Program builds upon the broad-based competencies achieved in a PGY1 residency, deepening the resident's ability to provide care in the most complex of cases or in the support of care through practice leadership. Therefore, the Ambulatory Care Residency Program provides residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and transforming both into improved medication therapy for patients. A resident who completes successfully the Ambulatory Care Residency Program should possess competencies that enable attainment of board certification in the practice area, where board certification for the practice area exists.

LEARNING EXPERIENCE DESCRIPTION
The Pharmacotherapy Clinic provides the resident with the opportunity to provide continuity of care to patients who require anticoagulation, enhance patient care through education, monitoring, and close follow-up, and reduce adverse events associated with anticoagulation therapy. The pharmacist will meet with the patient for a 30 minute visit (new patient) or a 15 minute visit (existing patient) during which time the pharmacist will perform INR POCT testing, with an MUSC approved device, as well as provide the patient with medication counseling in regards to medication changes, dietary changes, and potential bleeding problems, dosage adjustments will be made as necessary. This PGY2 experience is different than a PGY1 experience because the resident will build upon PGY1 skills. The resident will incorporate more evidence-based medicine concepts into recommendations and further refine ambulatory care skills to become an independent practitioner. The PGY2 resident will become an expert in ambulatory care and anticoagulation.

LEARNING EXPERIENCE ACTIVITIES

- Provide patient specific medication management services to promote ethical, compassionate, trusted care and positive outcomes
(R1.1.1; R1.1.2; R1.2.1; R1.2.2; R1.2.3; R2.6.1; R2.6.2;
R6.1.2; R2.10.1; R2.10.2)

- Independently design therapeutic regimens and monitoring plans to achieve desired therapeutic patient goals
(R2.1.1; 2.2.1; R2.3.1; R2.4.1; R2.4.2; R2.4.3; R2.4.4
R2.10.4; R6.3.1; R2.8.2; R2.10.1; R2.10.2; R2.10.3)

• Establish collaborative professional and patient-centered relationships
(R1.1.1; R1.2.1; 2.1.1; R2.2.1; R2.4.2; R2.6.1; R2.8.1;
R2.8.2; R2.9.1 R2.10.5; R2.10.6; R6.1.3; R6.4.2; R3.2.10; R3.2.11)

• Effectively educate health care professionals, patients, students, and residents on drug related topics/issues
(R 2.5.1; R 2.5.2; R3.2.9; R3.2.10; R5.1.1; R5.1.4)

• Use organizational and time management skills to fulfill practice responsibilities/duties
(R2.2.1; R2.7.1; R2.12.1; R2.12.2. R2.13.1; R2.13.3;
R2.13.4)

• Design advanced and evidence-based therapeutic regimens and monitoring plans to achieve desired therapeutic patient goals
(R2.62; R2.7.1 R2.10.5; R2.10.6; R2.11.1; R2.11.2)

• Demonstrate leadership and practice management skills
(R3.1.1; R3.1.4; R3.2.1; R3.2.2; R3.2.3; R3.2.4; R3.2.5)

• Utilize effective and efficient communications skills
(R2.13; R2.13.2; R3.1.1; R3.1.2; R3.2.6; R3.2.7; R3.2.8)

REQUIREMENTS OF LEARNING EXPRERIENCE

Required hours
8:00 AM – 4:30 PM
As patient care requires, the above listed times may vary

Required meetings for PGY2
Ambulatory Care Group Meetings (4th Thursday of the month at 12:00pm)
Ambulatory Care Journal Club (3rd Monday of the month at 3:00pm)
Ambulatory Care Discussion Group (2nd Wednesday of the month at 2:00pm)
Department of Pharmacy Meeting (monthly)
Topic Review Lunch (1st Tuesday of the month at 12:00pm)

Required presentations for PGY2
1-2 small presentations to AmCare students (topic to be decided by the preceptor and resident)

Suggested readings for PGY2
An extensive bibliography (see attachment) is provided to the resident.

ROTATION PRECEPTOR(S)
Pamela J Mazyck, PharmD, MSCR, BCPS, CDE
Pager – 11330
Phone – 843-792-3377

E-mail: mazyckpj@musc.edu

The resident will also have significant interactions with the following pharmacist:

Jennifer N. Mazur, Pharm, CDE
Pager – 12327
Phone – 843-881-2360
E-mail: mazurjn@musc.edu

METHOD OF EVALUATION

Evaluation of residents will be based on the learning experience objectives outlined by the Residency Program Director (RPD). The RPD will identify the specific goals and objectives on which the resident will be evaluated (available in E-Value). The preceptor and resident will review the resident's customized plan and the learning experience introduction document on the first day of rotation. Feedback will include, but not be limited to, verbal and written mid-point and end of rotation evaluations.

Key References in Anticoagulation Therapy

Consensus Guidelines

Scheife RT, Vanscoy GJ editors. Consensus on contemporary issues with unfractionated heparin:Challenges in Variation and Responsiveness. Pharmacotherapy 2004;24(part2):S 101-164.

Hirsh J, Guyatt G, Albers GW, et al. The Seventh ACCP Conference on Antithrombotic andThrombolytic Therapy. Chest 2004 126:172S-173S.

Hirsh J, Raschke R. Heparin and Low Molecular Weight Heparin: The Seventh ACCP Conference onAntithrombotic and Thrombolytic Therapy. Chest 2004 126:188S-203S.

Schunemann HJ, Munger H, Brower S, et al. Methodology for guideline development for the SeventhAmerican College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126:174S-178S.

Schunemann HJ, Cook D, Grimshaw J, et al. Anthithrombotic and Thrombolytic Therapy: FromEvidence to Application. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126:688S-696S.

Anticoagulation prior to Surgery

Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: asystematic review. Arch Intern Med. 2003 Apr 28;163(8):901-8.

Kearon C: Perioperative management of long-term anticoagulation. Semin Thromb Hemost 1998; 24Suppl 1: 77-83.

Lanzat M, Danna AT, Jacobson DS: New protocols for perioperative management of podiatric patients taking oral anticoagulants. J Foot Ankle Surg 1994 Jan-Feb; 33(1): 16-20.

Madura JA, Rookstool M, Wease G: The management of patients on chronic Coumadin therapy undergoing subsequent surgical procedures. Am Surg 1994 Jul; 60(7): 542-6; discussion 546-7.

LMWH Safety

Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.Arch Intern Med. 2000;160:2199-207.

Levine M, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl J Med. 334:677-681, 1996

McKean, S. Enoxaparin (Lovenox ®)-Home DVT Treatment Program, Harvard Community Health Program, 1998.

Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84:478-80, A10.

Weitz J. Low-Molecular-Weight Heparins. N Engl J Med 1997;337:688-698.

Anticoagulation for Prevention of DVT/PE

Geerts, W.H; et al**.** Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:338S-400S.

Goldhaber, S.; Turpie, A; Prevention of Venous Thromboembolism Among Hospitalized Medical Patients. Circulation. 2005;111: e1-e3.

Air Travel & DVT/PE Risk

Ansell JE. Air Travel and Venous Thromboembolism -- Is the Evidence In? N Engl J Med. 2001 Sep 13;345(11):828-9.

Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C, Cupa M, Adnet F.Severe pulmonary embolism associated with air travel. N Engl J Med. 2001 Sep 13;345(11):779-83

Martinelli, I.; et al: Risk of Venous Thromboembolism After Air Travel: Interaction With Thrombophilia and Oral Contraceptives *Arch Intern Med* 2003 163: 2771-2774.

Anticoagulation – Therapeutic Considerations

Ansell JE. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management. *Semin Vasc Med.* 2003 Aug;3(3):261-70.

Beyth RJ, Quinn LM, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.

Bussey, H; Managing Excessive Warfarin Anticoagulation. Ann Intern Med. 2001;135:460-462.

Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998;79:1116-8.
Cortelazzo S, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Hemost. 1993;69:316-320.

Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J. 1982;103:445-446.

Ginsberg JA, Crowther MA, White RH, Ortel TL: Anticoagulation therapy. Hematology (Am Soc Hematol Educ Program). 2001;:339-57.

Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, SilversteinMD. Bleeding and thromboembolism during anticoagulant therapy: A population based study in Rochester, Minnesota. Mayo Clin Proc.1995:70:725-733.

Handin RL Anticoagulant, fibrinolytic, and antiplatelet therapy. In: Braunwald E et al. (eds) Harrison´s principles of internal medicine. McGraw-Hill, NY, 758-761 Anticoag. Therapy 2001.

Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S-469S.

Kelly JJ et al. Safety, Effectiveness, and Efficiency: A Web-Based Virtual Anticoagulation Clinic. Joint Commission Journal on Quality and Safety, December 2003, Volume 29, Number 12.

Landefeld S, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Amer J Med. 1993;95:315-328.

Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med. 1991;229:351-355.

Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D.: Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003 Nov 10;163(20):2469-73.

Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.

Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regularanticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis. 1993;4:739-41.
Pettiti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med. 1986;81:255-259.

Phan, TG, et al. Safety of Discontinuation of Anticoagulation in Patients With Intracranial Hemorrhage at High Thromboembolic Risk. Arch Neurol. 2000;57:1710-1713.

Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol. 1979;8: 243-7.

Sixty Plus Reinfarction Study Research Group. Risks of longterm oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group. Lancet. 1982;I:62-68.

van der Meer FJM, Rosendaal FR, vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors. Arch Intern Med. 1993;153:1557-1562.

Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc.2000;131:77-81.

Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med. 1997;126:959-62.

Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. AnnIntern Med. 1994;121:676-83.

White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy:changes in the international normalized ratio. Ann Intern Med. 1995;122:40-2.

White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med. 1996;156:1197-1201.

Wilson D, Watson HG, and Crowther MA**:** Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. Can. Med. Assoc.J., Mar 2004; 170: 821 - 824.

Age-related risks

Gage BF, Fihn SD, White RH., Warfarin therapy for an octogenarian who has atrial fibrillation. AnnIntern Med. 2001 Mar 20;134(6):465-74.

Gurwitz J, Goldberg R, Holden A, Knapic N, Ansell J. Agerelated risks of long-term oral anticoagulanttherapy. Arch Intern Med. 1988;148:1733-1736.
Issacs C, Paltiel O, Blake G, Beaudet M, Conochie L, Leclerc J. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture. Am J Med. 1994; 96:487-491.

Joglekar M, Mohanaruban K, Bayer AJ, Pathy MSJ. Can old people on oral anticoagulants be safely managed as outpatients? Postgrad Med J. 1988;64:775-777.

Massicotte P.et al.; Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor Journal of Pediatrics, Vol. 127 (1995), No. 3, 389-394.

Michelson AD, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. Chest. 1998;114:748S-769S.

Wickramasinghe LSP, Basu SK, Bansal SK. Long-term oral anticoagulant therapy in elderly patients.Age Ageing. 1988;17:388-396.

Clinic Settings

Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals:death rates, length of stay, Medicare charges, bleeding complications, and transfusions. *Pharmacother.* 2004;24(8):953-963.

Bussey HI, Rospond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy. 1989;9:214-219.

Charney R, Leddomado E, Rose DN, Fuster V. Anticoagulation clinics and the monitoring of anticoagulant therapy. Int J Cardiol. 1988;18:197-206.

Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: Experience with an anticoagulation clinic. Arch Intern Med. 1984;144:1966-1968.

Garabedian-Ruffalo SM, Gray DR, Sax MJ, et al. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm. 1985;42:304-308.

McInnes GT, Helenglass G. The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond. 1987;21:42-45.

Petty GW, Lennihan L, Mohr JP, et al. Complications of longterm anticoagulation. Ann Neurol. 1988;23:570-574.